Abstract: An electronic device is provided, including a main body and a camera module. The camera module has a frame, a lens unit disposed in the frame, a guiding member, and a hinge. The guiding member is affixed to the main body and has a rail and a spring sheet. The hinge pivotally connects to the frame and the guiding member. When the camera module is in the retracted position, the camera module is hidden in a recess of the main body. When the camera module slides out of the recess from the retracted position along the rail into the operational position, the spring sheet is pressed by the hinge to increase the friction between the hinge and the guiding member.

Abstract: The present teaching relates to a method and system for path planning. Information of a current pose of a robotic arm having a plurality of operable segments is obtained. The information includes a plurality of values, each of which corresponds to an angle formed between consecutive operable segments of the robotic arm. A desired pose where the robotic arm needs to reach is also obtained. An angle step-value is computed for the current pose of the robotic arm based on a function of a distance between the current pose and the desired pose, wherein the angle step value is to be used to determine a plurality of candidate next poses of the plurality of operable segments. One or more of candidate next poses is selected based on at least one criterion, and a trajectory is determined from the current pose to the desired pose based on the selected next poses.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Abstract: Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.

Abstract: This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and/or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

Abstract: A chair backrest swing structure includes a chassis connecting seat, a backframe connecting seat and an elastic buffer and reset member. The chassis connecting seat is configured to be cooperatively mounted with a chassis. The backframe connecting seat is configured to be cooperatively mounted with a backframe. The backframe connecting seat is rotatably cooperated with the chassis connecting seat. The elastic buffer and reset member is configured to enable that the backframe connecting seat may implement buffer and reset when swung left and right on the chassis connecting seat.

Abstract: This description provides novel strategies and methods for treatment of hyperproliferation conditions such as keloids, lung fibrosis, and lung cancer with the use of bi-functional molecules that target growth factors. A bifunctional hepatoma-derived growth factor (HDGF)-specific antibody for these methods comprises at least one complementarity determining region (CDR) specific for HDGF, at least one receptor domain that specifically binds to a growth factor selected from vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF?).

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Abstract: The present invention provides isolated nucleic acid molecules comprising short non-coding protein regulatory RNAs (sprRNA), variants, fragments and inhibitors thereof and compositions and methods of using the same.

Abstract: This description provides novel strategies and methods for treatment of hyperproliferation conditions such as keloids, lung fibrosis, and lung cancer with the use of bi-functional molecules that target growth factors. A bifunctional hepatoma-derived growth factor (HDGF)-specific antibody for these methods comprises at least one complementarity determining region (CDR) specific for HDGF, at least one receptor domain that specifically binds to a growth factor selected from vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF?).

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Abstract: The present invention provides isolated nucleic acid molecules comprising short non-coding protein regulatory RNAs (sprRNA), variants, fragments and inhibitors thereof and compositions and methods of using the same.

Abstract: The present invention discloses an improved extreme learning machine method based on artificial bee colony optimization, which includes the following steps: Step 1, generating an initial solution for SN individuals: Step 2, globally optimizing a connection weight ? and a threshold b for the extreme learning machine; Step 3, locally optimizing the connection weight ? and threshold b of the extreme learning machine; Step 4, if food source information is not updated within a certain time, transforming employed bees into scout bees, and reinitializing the individuals after returning to Step 1; and Step 5, extracting the connection weight ? and threshold b of the extreme learning machine from the best individuals, and verifying by using a test set. With the method provided by the present invention, the defect of worse results of the traditional extreme learning machine in classification and regression is overcomed, and effectively improves the results of classification and regression.

Abstract: The invention relates to dimeric proteins comprised of subunits having (i) recombinant lamprey variable lymphocyte receptor (VLR) diversity regions linked to (ii) multimerization domains. The dimeric proteins exhibit binding specificity for glycosylated antigens, and they may be used in methods of detecting or isolating glycans from a sample, and in methods of disease diagnosis, prognosis, progression monitoring, treatment, and imaging.